Sami Labs Limited

Sami-sabinsa Group Limited

Other

Semi Labs Limited

Majeed, Muhammed

Nagabhushanam, Kalyanam

Pandey, Anjali

Majeed, Anju

Bani, Sarang

Anjali Pandey

Kalyanam Nagabhushanam

Muhammed Majeed

Sarang Bani

Beena Bhat

Anju Majeed

Priti Vaidyanathan

Douglas Kalman

Suresh Karri

Lakshmi Mundkur

Shaheen Majeed

Bani Sarang

The invention discloses compositions comprising bisdemethoxycurcumin and methods for managing polycystic ovary syndrome (PCOS) and its associated conditions which include hormonal imbalance, obesity, hypothyroidism, hyperandrogenism, oxidative stress, inflammation, gut dysbiosis, hypercholesterolemia, cardiovascular complications, hyperglycemia and insulin resistance. The invention also discloses the potential of a curcuminoid composition comprising 20-80% w/w bisdemethoxycurcumin, 10-35% w/w demethoxycurcumin and 10-50% w/w curcumin for use in the therapeutic management of PCOS.

Compositions for management of polycystic ovary syndrome

The invention discloses a composition comprising not less than 20% w/w bisdemethoxycurcumin for regeneration of alveolar cells damaged in emphysematous conditions and for the therapeutic management of chronic obstructive pulmonary disease and acute respiratory distress syndrome. The composition further comprises 10-35% w/w demethoxycurcumin and 10-45% w/w curcumin. The composition is very suitable for treating COPD and ARDS due to viral infections, specifically COVID 19 and for improving lung function during prognosis.

Compositions for managing chronic obstructive pulmonary disease

The present invention discloses a method for therapeutic management of pulmonary fibrosis in mammals using a composition comprising iso-garcinol or octahydrocurcumin or a combination of iso-garcinol and octahydrocurcumin. The composition is very suitable for treating pulmonary fibrosis due to viral infections, specifically COVID 19 and for improving lung function during prognosis.

Therapeutic compositions and methods for pulmonary fibrosis

The present invention discloses a method for therapeutic management of atrophic gastritis and colitis using a composition comprisingMTCC 5856 individually or in combination with anthocyanins. The invention further discloses a method for preventing neoplastic transformation of mucosal cells in gastro-intestinal tract and improving gut barrier function in mammals using a composition comprisingMTCC 5856 individually or in combination with anthocyanins.

Compositions and methods for management of atrophic gastritis and colitis

The present invention discloses a composition comprising extracts of, standardized to contain 3-5% w/w total stilbenes, extracts ofsp., standardized to contain 20% w/w garcinol and extracts ofstandardized to contain not less than 10% w/w forskolin for the therapeutic management of diet induced obesity and weight gain and related conditions like liver dysfunction, NASH, NAFLD, liver cirrhosis, hypercholesterolemia, hyperlipidemia, kidney dysfunction by bringing about a reduction in body weight, increasing lean body mass and by normalizing the levels of liver enzymes, kidney markers and circulating lipids.

Compositions for weight loss

The present invention discloses a composition for the therapeutic management of male sexual dysfunction and related disorders. Specifically, the invention discloses a composition comprising 60-65% w/wextract, 12-18% w/wextract, 5-10% w/wextract, 12-18% w/wextract, 0.1-2% w/wextract, for use as an aphrodisiac.

Aphrodisiac composition and management of male sexual dysfunction

The present invention discloses a composition comprisingextract standardized to contain not less that 0.3% w/w S-allylcysteine,extract standardized to contain not less than 2% w/w nitrates,extract standardized to contain 0.1%-5% w/w thymoquinone, about 0.01%-10% w/w thymohydroquinone, about 20%-95% w/w fatty acids, about 0.001%-3% w/w &#x3b1;-hederin or hederagenin, andextract standardized to contain 3% w/w arjunoglucosides for use a prostaglandin transporter inhibitor. The invention also discloses the use of the aforementioned composition in the therapeutic management of hypertension and cardiovascular complications.

Composition for prostaglandin transporter inhibition and related therapeutic applications

Disclosed are methods of managing hypercholesterolemia using a composition of matter comprising the ethyl acetate fraction of the extract ofrhizomes standardized to contain 5% of total stilbenes.

Composition comprising scirpusin A and scirpusin B and anti-obesity potential thereof

Disclosed is a method of achieving optimal mammalian energy balance using forskolin on a particular physiological and developmental stage of the mammalian cellular system.

Process and compositions for achieving mammalian energy balance

Disclosed are methods of managing obesity and hypercholesterolemia using a composition of matter comprising the ethyl acetate fraction of the extract ofrhizomes standardized to contain 5% of total stilbenes.

Disclosed is a therapeutic management method of hypercholesterolemia in mammals. More specifically, the present invention relates to a method of reducing high levels of circulating cholesterol (hypercholesterolemia) in the blood stream of mammals, said method involving step of administering therapeutically effective amounts of Calebin A to said mammals to bring about the effects of (i) reducing the amount of total blood cholesterol levels; (ii) reducing the concentrations of low density lipoproteins (LDL) and very low density lipoproteins (VLDL); (iii) increasing the concentrations of high density lipoproteins (HDL) and (iv) reducing concentrations of serum triglycerides.

Method for the treatment of hypercholesterolemia

Disclosed is a composition comprising scirpusin A and scirpusin B and anti-obesity potential thereof. Also disclosed are methods of inhibiting adipogenesis using a composition comprising scirpusin A and scirpusin B. The present invention also disclosed methods of therapeutically managing obesity in mammals using a composition comprising scirpusin A and scirpusin B. Still further, the present invention also relates to a method of obtaining compositions comprising A. scirpusin A and scirpusin B and B. piceatannol and its dimers scirpusin A and scirpusin B through bioactivity guided fractionation of the rhizomes of

Composition comprising scirpusin A and scirpusin B and anti-adipogenesis/anti-obesity potential thereof

The present invention discloses the potential of Calebin A in inhibiting adipogenesis and applications thereof in obesity management. The present invention elucidates the potential of Calebin A to favorably modulate biochemical markers associated with obesity. Notable biomodulatory properties of Calebin A include inhibiting leptin production, increasing adiponectin expression and inhibiting local (adipocyte) and systemic inflammation caused by pro-inflammatory cytokines Tumor Necrosis Factor (TNF-&#x3b1;), Interleukin-6 (IL-6) and Interleukin-1 (IL-1&#x3b2;).

Anti-obesity potential of Calebin A

The novel therapeutic potential of Calebin A and compositions thereof to prevent pathological damage to mammalian articular cartilage is disclosed.

Growing community of inventors

Bengaluru, India

Anjali Pandey